Engaging Staff to Improve COVID-19 Vaccination Response at Long-Term Care Facilities (NCT05449418)
ENSPIRE: Engaging Staff to Improve COVID-19 Vaccination Response at Long-Term Care Facilities
๐ฉบ Plain-English Summary (8th-Grade Level)
The ENSPIRE study is a cluster-randomized comparative effectiveness trial being conducted within long-term care and residential facilities that will test a communication and engagement strategy for increasing COVID-19 booster vaccination rates against an enhanced usual care comparator (Centers for Disease Control and Prevention or other national organization vaccine education and communication materials) among facility staff. The communication and engagement strategy being tested includes (1) the development of materials co-designed with and tailored to facility staff whose primary language is a language other than English or who are from certain cultural affinity groups and (2) the distribution of the developed materials by members of the language/cultural affinity groups with peer advocacy activities (full intervention). The study is being conducted in Washington state and Georgia. Long-term care/residential facilities will be asked to furnish their staff booster rate at 4 timepoints: pre-intervention, and one month (timepoint 1), 3 months (timepoint 2), and 6 months (timepoint 3) post-intervention. Staff at participating long-term care facilities will be invited to complete three online surveys at 3 timepoints: pre-intervention, 3 months post-intervention and 6 months post-intervention. Long-term care facilities will be randomized to a trial arm following the pre-intervention data collection.
Who can join: Review the eligibility criteria below.
Location: Kaiser Permanente Georgia Center for Research and Evaluation โ Atlanta, Georgia
Age range: 18 Years
๐งช Interventions in This Study
- Full Intervention (BEHAVIORAL)
- Enhanced Usual Care (OTHER)
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (2 Sites)
- Kaiser Permanente Georgia Center for Research and Evaluation โ Atlanta, Georgia
- Kaiser Permanente Washington Health Research Institute โ Seattle, Washington
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in COVID-19
- COVID-19 and Cancer Consortium Registry โ Nashville, Tennessee
- Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients โ Sacramento, California
- COVID-19, Chronic Adaptation and Response to Exercise (COVID-CARE) โ Bethesda, Maryland
- Identification and Characterization of SARS-CoV-2 Specific CD8 T Cells in Humans โ Baltimore, Maryland
- Canadian Adaptive Platform Trial of Treatments for COVID-19 in Community Settings โ Calgary, Alberta
- A Nasal Treatment for COVID-19 โ Indianapolis, Indiana
Explore by condition: All COVID-19 clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.